Bristol-Myers Squibb Company — SEC Form 4 Filings
SEC Form 4 Data
Track insider buying and selling activity for Bristol-Myers Squibb Company (BMY). Data sourced from SEC EDGAR Form 4 filings and analyzed by StoxPulse AI for significance.
9
$0.00 total
11
$2.7M total
0.8x
Neutral Signal
20
Form 4 transactions
Buy − Sell value
Sale · Apr 1, 2026
Short · Buy
Bristol-Myers Squibb Company insiders filed 20 Form 4 transactions in the period analyzed: 9 purchases totaling $0.00 and 11 sales totaling $2.7M. That puts the buy-to-sell ratio at 0.82, which we read as neutral on a directional basis.
The most active filer was Short Bartie Wendy with 8 transactions in this window. 18 of the 20 filings are flagged as routine — typically 10b5-1 scheduled trades rather than discretionary signals.
Form 4 filings are point-in-time disclosures and do not constitute investment advice. Routine sales under pre-arranged 10b5-1 plans should not be read as bearish.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Short Bartie Wendy | EVP, Corporate Affairs | Buy | 8,040 | $0.00 | $0.00 | 2026-06-03 |
| Short Bartie Wendy | EVP, Corporate Affairs | Sale | 3,876 | $54.72 | $212K | 2026-06-03 |
| Lenkowsky Adam | EVP, Chief Commercial Officer | Buy | 1,373 | $0.00 | $0.00 | 2026-05-01 |
| Lenkowsky Adam | EVP, Chief Commercial Officer | Sale | 599 | $58.22 | $35K | 2026-05-01 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Buy | 3,307 | $0.00 | $0.00 | 2026-04-01 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Sale | 1,692 | $61.73 | $104K | 2026-04-01 |
| Elkins David V | EVP, Chief Financial Officer | Sale | 25,519 | $61.60 | $1.6M | 2026-04-01 |
| Elkins David V | EVP, Chief Financial Officer | Sale | 4,481 | $62.05 | $278K | 2026-04-01 |
| Short Bartie Wendy | EVP, Corporate Affairs | Buy | 639 | $0.00 | $0.00 | 2026-03-10 |
| Short Bartie Wendy | EVP, Corporate Affairs | Sale | 205 | $60.13 | $12K | 2026-03-10 |
| Short Bartie Wendy | EVP, Corporate Affairs | Buy | 749 | $0.00 | $0.00 | 2026-03-10 |
| Short Bartie Wendy | EVP, Corporate Affairs | Sale | 242 | $60.13 | $15K | 2026-03-10 |
| Short Bartie Wendy | EVP, Corporate Affairs | Buy | 4,495 | $0.00 | $0.00 | 2026-03-10 |
| Short Bartie Wendy | EVP, Corporate Affairs | Sale | 828 | $60.13 | $50K | 2026-03-10 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Buy | 2,448 | $0.00 | $0.00 | 2026-03-10 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Sale | 1,112 | $60.13 | $67K | 2026-03-10 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Buy | 3,293 | $0.00 | $0.00 | 2026-03-10 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Sale | 1,503 | $60.13 | $90K | 2026-03-10 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Buy | 19,760 | $0.00 | $0.00 | 2026-03-10 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | Sale | 5,145 | $60.13 | $309K | 2026-03-10 |
Insider trading data for Bristol-Myers Squibb Company (BMY) is sourced directly from SEC Form 4 filings on the EDGAR database. Corporate insiders — including directors, officers, and shareholders owning more than 10% of the company — are legally required to report their transactions within two business days.
Insider purchases are often considered a bullish signal because executives are using their own money to buy shares, suggesting they believe the stock is undervalued. Insider sales, on the other hand, are more nuanced — they can reflect routine diversification plans (known as 10b5-1 plans), tax obligations, or genuine concerns about the company's outlook.
StoxPulse's AI system analyzes each BMY insider transaction to determine whether it appears routine or notable. We track the buy/sell ratio, total transaction values, and patterns over time to provide a clear picture of insider sentiment for Bristol-Myers Squibb Company.
AI earnings, financials, news & more
Translate any filing into plain English
Disclaimer: Insider trading data for Bristol-Myers Squibb Company (BMY) is sourced from SEC Form 4 filings and is provided for informational purposes only. Insider transactions should not be the sole basis for investment decisions. Always consult a qualified financial advisor.
Join the waitlist to receive instant AI notifications when Bristol-Myers Squibb Company insiders buy or sell shares.
Join the Waitlist